GlobeNewswire
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
📈
AI Sentiment
Highly Positive
9/10
- Home
- IMMP
IMMP
Immutep Limited
as of 12-17-2025 12:10pm EST
$2.63
+$0.14
+5.62%
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Chart Type:
Time Range:
| Founded: | 1987 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 264.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.32 - $3.53 | Next Earning Date: | 02-22-2026 |
| Revenue: | $3,306,742 | Revenue Growth: | 31.28% |
| Revenue Growth (this year): | -9.89% | Revenue Growth (next year): | N/A |
Latest Immutep Limited News
IMMP Breaking Stock News: Dive into IMMP Ticker-Specific Updates for Smart Investing
Simply Wall St.
High Growth Tech Stocks To Watch In December 2025
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
ASX Penny Stocks Spotlight: DUG Technology Among 3 Noteworthy Picks
âž–
AI Sentiment
Neutral
5/10
Insider Monkey
Immutep Limited (IMMP): Firm Reports Positive Data from Trials
📈
AI Sentiment
Highly Positive
8/10
Compare IMMP vs Leading Stocks
See how IMMP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMMP Immutep Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.